Stages I-III Pancreatic Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (01-23-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (08-17-2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (06-24-2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more... Continue Reading

Ruxolitinib Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (06-2-2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with ruxolitinib plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer... Continue Reading

Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients (05-23-2014)

In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and Treatment, researchers reported that a combination therapy of gemcitabine and radioimmunotherapy (fractionated doses... Continue Reading

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET) (06-2-2011)

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type of cancer that develops in the hormone-producing cells... Continue Reading

Afinitor Approved for Pancreatic Neuroendocrine Tumors (05-10-2011)

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon type of cancer that develops in the hormone-producing... Continue Reading

New Approach to Immune Therapy Shows Promise against Pancreatic Cancer (04-1-2011)

An investigational type of immune therapy that attacks the tissue around a tumor has shown promise in a small study of patients with advanced pancreatic cancer. These results were published in the journal Science. Immune therapies stimulate the body’s... Continue Reading

Addition of Axitinib Fails to Improve Pancreatic Cancer Outcomes (02-23-2011)

Among patients with advanced pancreatic cancer, treatment with a combination of Gemzar® (gemcitabine) and the investigational drug axitinib did not result in better outcomes than treatment with Gemzar alone. The results of this Phase III clinical trial... Continue Reading

Gemzar Versus 5-FU for Adjuvant Treatment of Pancreatic Cancer (09-21-2010)

A large randomized study demonstrated no significant improvement in survival with Gemzar® (gemcitabine) versus 5-fluorouracil (5-FU) for the adjuvant (post-surgery) treatment of pancreatic cancer. These findings were recently published in the Journal... Continue Reading

Next Page »